article
Outsmarting immune suppression through GPCR innovation
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
List view / Grid view
Monoclonal Antibody
article
Future-proofing drug development with GenAI
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
news
Scientists develop immunotherapy to disarm fat-fuelled tumours
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
news
Targeting drug resistance in HER2-positive breast cancer models
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
news
Rare genetic variant blocks common Alzheimer’s disease risk factor
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
article
Latest developments in COVID-19 research
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
article
Women in STEM with Dr Jane Osbourn
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
news
Experimental mAbs show promise against Epstein-Barr virus
Researchers find monoclonal antibodies provided nearly complete protection against EBV infection and lymphoma when tested in mice.
news
New findings show a monoclonal antibody could target heroin addiction
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
news
Newly discovered SARS-CoV-2-like virus could infect humans and resist vaccines
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
article
In search of COVID-19 antibodies
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
article
T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
article
Monoclonal antibodies as a strategy to fight cancer
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
article
Drug Target Review Antibodies ebook 2022
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
